Health tech can't burn cash indefinitely like other tech sectors due to long timelines and complexity. Founders must design their company to achieve profitability at multiple stages, creating self-sustaining platforms before pursuing the next level of growth and investment.

RoboCath deliberately designed its platform to be compatible with all device brands. This open-ecosystem approach lowers the barrier to adoption, as physicians don't need to abandon their preferred tools, a key advantage over competitors who might pursue exclusive partnerships.

A successful MedTech platform can be a blueprint for expansion. By identifying new disease areas with similar core problems (e.g., imaging-based diagnosis delays), a company can replicate its proven strategies for product development, evidence generation, and partnerships.

Successful MedTech innovation starts by identifying a pressing, real-world clinical problem and then developing a solution. This 'problem-first' approach is more effective than creating a technology and searching for an application, a common pitfall for founders with academic backgrounds.

Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

A common strategic error in biotech is assuming a therapeutic delivery system that works for one part of the body (e.g., the liver) constitutes a universal 'platform.' In reality, effective platforms must be built organ-by-organ; a system for targeting tumors is fundamentally different from one for T-cells or kidneys.

Companies like Amazon (from books to cloud) and Intuitive Surgical (from one specific surgery to many) became massive winners by creating new markets, not just conquering existing ones. Investors should prioritize businesses with the innovative capacity to expand their TAM, as initial market sizes are often misleadingly small.

Carvolix is strategically designing its robotic and AI platform to be compatible with heart valves from all major manufacturers like Edwards and Medtronic. This "agnostic" approach allows them to sell *to* the entire ecosystem rather than competing *within* it, positioning their technology as a universal upgrade that any hospital can adopt regardless of its preferred valve supplier.